Cat. #161771
OV-1946 cell line
Cat. #: 161771
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from matched ascites from case TOV-1946
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Ouellet et al. 2008. BMC Cancer. (8):152. PMID: 18507861
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: OV-1946 cell line
- Alternate name: OV-1946
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from matched ascites from case TOV-1946
- Donor: Grade 3 Stage IIIC; Mutations: TP53 Exon 8; Pre-treatment
- Morphology: Able to form less compact spheroids and expressed Krt7
- Growth properties: Adherent
- Crispr: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell line derived from matched ascites from TOV-1946. Cell line derived from ascites of chemotherapy naive patient who presented poorly differentiated (grade 3) serous papillary cystadenocarcinoma at stage IIC
- Production details: Established from a mass of cells from ascites of patient 1946. Mass was macro-dissected and kept in 100mm petri dish for 27 days where they reached 80% confluence. Tissue was discarded and cells were divided 2:3 every week for the first 15 passages and 1:2 twice a week until passage 70. Cells were mantianed and divided 1:5 twice a week afterwards
- Additional notes: Patient 1946 had no known familial history of cancer and passed from post-operative complications
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
- Cultured in antibiotics: Amphotericin B and Gentamicin
References
- Sauriol et al. 2023. Sci Rep. 27
- 13(1):3334. PMID: 36849518 Sevinyan et al. 2022. Cancers (Basel). 16
- 14(22):5628. PMID: 36428724 Brodeur et al. 2021. Sci Rep. 14
- 11(1):18183. PMID: 34521878 Communal et al. 2021. Int J Mol Sci. 18
- 22(10):5325. PMID: 34070214 Patra et al. 2020 PLoS One. 31
- 15(12):e0244549. PMID: 33382759
